Human single-stranded DNA protein 1 (hSSB1): a prognostic factor and target for non-small cell lung cancer (NSCLC) treatment

被引：0
|
作者：
Boucher, D. [1 ,2 ]
Ashton, N. [1 ,2 ]
Suraweera, A. [1 ,2 ]
Burgess, J. [1 ,2 ]
Bolderson, E. [1 ,2 ]
Barr, M. [3 ]
Gray, S. [3 ]
Gately, K. [3 ]
Adams, M. [1 ,2 ]
Croft, L. [1 ,2 ]
Richard, D. [1 ,2 ]
O'Byrne, K. [1 ,2 ]
机构：
[1] Queensland Univ Technol, Brisbane, Qld, Australia
[2] Translat Res Inst, Brisbane, Qld, Australia
[3] Trinity Coll Dublin, Thorac Oncol Res Grp, Dublin, Ireland
来源：
LUNG CANCER | 2019年 / 127卷
关键词：
D O I：
10.1016/S0169-5002(19)30084-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
40
引用
收藏
页码：S17 / S17
页数：1
相关论文
共 50 条
  • [21] An Exploration of Small Molecules That Bind Human Single-Stranded DNA Binding Protein 1
    Schuurs, Zachariah P.
    Martyn, Alexander P.
    Soltau, Carl P.
    Beard, Sam
    Shah, Esha T.
    Adams, Mark N.
    Croft, Laura V.
    O'Byrne, Kenneth J.
    Richard, Derek J.
    Gandhi, Neha S.
    BIOLOGY-BASEL, 2023, 12 (11):
  • [22] TREATMENT OF ELDERLY NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS - A PROGNOSTIC INDEX
    Clement, D.
    Marinca, M.
    Miron, L.
    ANNALS OF ONCOLOGY, 2008, 19 : 209 - 209
  • [23] Endothelin-1 is a novel prognostic factor in non-small cell lung cancer
    Arun, C
    DeCatris, M
    Hemingway, DM
    London, NJM
    O'Byrne, KJ
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2004, 19 (04): : 262 - 267
  • [24] Aberrant DNA methylation of OLIG1, a novel prognostic factor in non-small cell lung cancer
    Brena, Romulo M.
    Morrison, Carl
    Liyanarachchi, Sandya
    Jarjoura, David
    Davuluri, Ramana V.
    Otterson, Gregory A.
    Reisman, David
    Glaros, Selina
    Rush, Laura J.
    Plass, Christoph
    PLOS MEDICINE, 2007, 4 (03): : 572 - 584
  • [25] Inhibition of AKT-1 for the treatment of human non-small cell lung cancer (NSCLC) in-vitro
    Chorner, Paige M.
    Moorehead, Roger A.
    CANCER RESEARCH, 2017, 77
  • [26] The quantification of DNA in the serum is a useful prognostic factor in advanced non-small cell lung cancer (NSCLC) patients.
    Berrocal, A
    Sirera, R
    Camps, C
    Bremnes, RM
    Alberola, V
    Bayo, P
    Safont, MJ
    Blasco, A
    Taron, M
    Sanchez, JJ
    Rosell, R
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 669S - 669S
  • [27] Prognostic and therapeutic aspects of non-small cell lung cancer (NSCLC)
    Biasco, G
    Tamberi, S
    2ND INTERNATIONAL CONGRESS OF THORAX SURGERY, 1998, : 7 - 8
  • [28] Prognostic value of ERCC1 expression in advanced non-small cell lung cancer (NSCLC)
    Kollmeier, Jens
    Blum, Torsten
    Misch, Daniel
    Roth, Andreas
    Boch, Christian
    Gruening, Wolfram
    Crolow, Catharina
    Griff, Sergej
    Mairinger, Thomas
    Bauer, Torsten T.
    EUROPEAN RESPIRATORY JOURNAL, 2012, 40
  • [29] Prognostic impact of XPO1 mutations in metastatic non-small cell lung cancer (NSCLC).
    Asad, Mohammad Fahad B.
    Al Hallak, Mohammed Najeeb
    Sukari, Ammar
    Baca, Yasmine
    Xiu, Joanne
    Mamdani, Hirva
    Uprety, Dipesh
    Kim, Chul
    Xia, Bing
    Liu, Stephen V.
    Nieva, Jorge J.
    Lopes, Gilberto
    Borghaei, Hossein
    Demeure, Michael J.
    Raez, Luis E.
    Ma, Patrick C.
    Puri, Sonam
    Korn, Wolfgang Michael
    Azmi, Asfar S.
    Nagasaka, Misako
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [30] The cost of non-small cell lung cancer (NSCLC) treatment
    Vergnenegre, A.
    ONCOLOGIE, 2012, 14 (05) : 310 - 315
12345